Important Safety Information

Last Updated: June 3, 2025

Refer to the Important Safety Information below for details on the intended use, possible risks, side effects, considerations for specific populations, and interactions with other medications related to the advertised prescription treatments.

Coby recommends reporting any adverse side effects of medications to your healthcare provider and the dispensing pharmacy. To report suspected adverse reactions to the FDA, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

IN CASE OF ANY EMERGENCY, PLEASE CALL 911 OR GO SEEK CARE AT THE NEAREST EMERGENCY ROOM.

‍

Coby Advertisements

Advertisements from cobyhealth.com are sponsored by Coby Health LLC to advertise and market Coby’s services. Advertisements may feature paid actors or portrayals. Testimonials, endorsements, or appearances by actual Coby users will be clearly marked. Results from medications and programs can differ, and no specific outcomes are guaranteed.

Coby Services

Coby offers and facilitates access to consultations with licensed healthcare professionals to assess the medical suitability of the advertised treatments and plans. Through its services, Coby may coordinate the fulfillment of prescriptions via a third-party pharmacy network. Coby does not offer medical advice, dispense prescription medications, or operate as a licensed healthcare provider or pharmacy. Instead, Coby offers software and technology solutions to support medical consultations and prescription fulfillment. For further information, please see our Terms of Service.

Prescription Medications

Prescription medications require a consultation with a licensed medical provider, who will determine if a prescription is appropriate. The decision to prescribe is at the sole discretion of the licensed medical professional, and access to medications or treatment plans is not guaranteed. Prescriptions issued by these professionals may be available through Coby’s software platform and can be filled by licensed pharmacies.

Prescription medications carry risks. To review risks and side effects, please see the information below and speak with your clinician.

Ownership of Trademarks

Ozempic® and Wegovy® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. Coby Health has no ownership over any FDA-approved medications or products or related trademarks. To learn more about Novo Nordisk products, please visit https://www.novonordisk.com/our-products/our-medicines.html. To learn more about Eli Lilly products, please visit https://www.lilly.com/our-medicines/current-medicines.

Compounded Medications

In certain situations, healthcare providers may prescribe compounded medications, which are custom-prepared by certified compounding pharmacies based in the U.S. These medications are not FDA-approved for safety or effectiveness but may be used when alternatives are not available or appropriate.

Coby may coordinate the filling of both FDA-approved and compounded medications through a network of licensed pharmacies across the United States. Compounded medications are tailored to individual patient needs based on a healthcare provider’s prescription, which may differ from commercially available options. FDA-approved substitutes may exist.

Compounded Semaglutide‍

Important Safety Information Regarding Compounded Semaglutide Products

Please be aware that compounded drugs are not FDA-approved and do not undergo clinical studies to evaluate for safety and efficacy, unlike FDA-approved commercially available products. Compounded products may still be legally prescribed, and your healthcare provider may issue you a prescription for compounded semaglutide based on your medical consultation. For more information, see the FDA's concerns with compounded GLP-1 medications used for weight loss.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:

30 kg/m2 or greater (obesity); or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Speak with your healthcare provider to see if compounded semaglutide may be right for you.

Compounded semaglutide may cause serious side effects, including:

Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, semaglutide caused thyroid tumors, including thyroid cancer. It is not known if semaglutide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in humans.

Who should not use compounded semaglutide:

Do not use semaglutide if you or any family member has ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use compounded semaglutide if you have had a serious allergic reaction to semaglutide in the past.

Before starting compounded semaglutide, tell your healthcare provider if you have any other medical conditions, including if you:

Have or have had problems with your pancreas or kidneys
Have type 2 diabetes and a history of diabetic retinopathy.
Have or have had depression, suicidal thoughts, or mental health issues.
Are pregnant or plan to become pregnant. Semaglutide should not be used during pregnancy and there may be potential risks to an unborn baby from exposure to semaglutide during pregnancy. You should stop using semaglutide for at least 2 months before you plan to become pregnant.
Are breastfeeding or plan to breastfeed. It is not known if semaglutide passes into your breast milk.

Serious side effects can occur with semaglutide. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dosage changes. Semaglutide may cause serious side effects, including:

Thyroid C-Cell Tumors. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, semaglutide caused thyroid tumors, including thyroid cancer. It is not known if semaglutide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in humans.
Paralysis of the stomach (gastroparesis). The symptoms of gastroparesis may include feeling full shortly after starting a meal, feeling full long after eating a meal, nausea, and vomiting. Contact your healthcare provider if you experience any of these symptoms.
Inflammation of your pancreas (pancreatitis). Stop using semaglutide and contact your healthcare provider immediately if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting.
Gallbladder problems. Semaglutide may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Contact your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools.
Increased risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take semaglutide.
Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
Serious allergic reactions. Stop using semaglutide and seek medical attention if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.
Change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision with semaglutide.
Increased heart rate. Semaglutide may increase your heart rate while you are at rest. Talk to your healthcare provider if you feel your heart racing or pounding.‍
Depression or thoughts of suicide.You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Contact your healthcare provider immediately if you have any mental changes that are new, worse, or worry you.

The most common side effects of semaglutide may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, gas, stomach flu, heartburn, and runny nose or sore throat.

Compounded semaglutide administration. Compounded semaglutide can be taken with or without food. The medication is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. For detailed instructions on how to administer your dose, please speak with your healthcare provider. They will guide you on a treatment regimen and explain to self-administer the medication. You should not change your dosing regimen or stop taking semaglutide as prescribed without first discussing with your healthcare provider.

This information is not comprehensive. Please discuss with your healthcare provider any questions or concerns you have regarding semaglutide.

‍

Compounded Tirzepatide

Important Safety Information Regarding Compounded Tirzepatide Products

Please be aware that compounded drugs are not FDA-approved and do not undergo clinical studies to evaluate for safety and efficacy, unlike FDA-approved commercially available products. Compounded products may still be legally prescribed, and your healthcare provider may issue you a prescription for compounded tirzepatide based on your medical consultation. For more information, see the FDA's concerns with compounded GLP-1 medications used for weight loss.

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of:

30 kg/m2 or greater (obesity); or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease).

Speak with your healthcare provider to see if compounded tirzepatide may be right for you.

Compounded tirzepatide may cause serious side effects, including:

Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is not known whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.

Who should not use compounded tirzepatide:

Do not use tirzepatide if you or any family member has ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use compounded tirzepatide if you have had a serious allergic reaction to tirzepatide in the past.

Before starting compounded tirzepatide, tell your healthcare provider if you have any other medical conditions, including if you:

Have or have had problems with your pancreas or kidneys.

Have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food.
Have a history of diabetic retinopathy.
Have or have had depression, suicidal thoughts, or mental health issues.
Are pregnant or plan to become pregnant. Tirzepatide should not be used during pregnancy and there may be potential risks to an unborn baby from exposure to tirzepatide during pregnancy. You should discuss with your healthcare provider whether and how you should stop using tirzepatide before you plan to become pregnant.
Are breastfeeding or plan to breastfeed. It is not known if tirzepatide passes into your breast milk.

Tell your healthcare provider about all the medicines you take. This includes prescription medications, over-the-counter medicines, vitamins, and herbal supplements. Tirzepatide may affect the way some medicines work, and some medicines may affect the way tirzepatide works. If you are taking medicines to treat diabetes, including insulin or sulfonylureas, please let your healthcare provider know as tirzepatide could increase your risk of low blood sugar.

Serious side effects can occur with tirzepatide. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dosage changes. Tirzepatide may cause serious side effects, including:

Thyroid C-Cell Tumors. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, tirzepatide caused thyroid tumors, including thyroid cancer. It is not known if tirzepatide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in humans.
Paralysis of the stomach (gastroparesis). The symptoms of gastroparesis may include feeling full shortly after starting a meal, feeling full long after eating a meal, nausea, and vomiting. Contact your healthcare provider if you experience any of these symptoms. Tirzepatide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
Inflammation of your pancreas (pancreatitis). Stop using tirzepatide and contact your healthcare provider immediately if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting.
Gallbladder problems. Tirzepatide may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Contact your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools.
Increased risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take tirzepatide.
Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
Serious allergic reactions. Stop using tirzepatide and seek medical attention if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.
Change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision with tirzepatide.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use tirzepatide with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.
Depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Contact your healthcare provider immediately if you have any mental changes that are new, worse, or worry you.

The most common side effects of tirzepatide include: nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of tirzepatide. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.

Compounded tirzepatide administration. The medication is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. For detailed instructions on how to administer your dose, please speak with your healthcare provider. They will guide you on a treatment regimen and explain to self-administer the medication. You should not change your dosing regimen or stop taking tirzepatide as prescribed without first discussing with your healthcare provider.

This information is not comprehensive. Please discuss with your healthcare provider any questions or concerns you have regarding tirzepatide.

‍

Compounded NAD+ Injections

NAD+ injections are generally considered safe when administered properly. However, as with any medical treatment, there may be risks and potential side effects. Here are some important safety points to consider:

Injection Site Reactions: Mild bruising or soreness at the injection site is the most common side effect. This typically resolves on its own.
Allergic Reactions: Although rare, some individuals may experience allergic reactions to NAD+ injections. If you notice any signs of an allergic response (such as rash, itching, or difficulty breathing), seek immediate medical attention.
Interactions with Medications: NAD+ injections may interact with certain medications. Always inform your healthcare provider about any other drugs you’re taking to avoid potential interactions.
Underlying Health Conditions: Consult with your doctor before undergoing NAD+ therapy, especially if you have underlying health conditions. They can assess whether NAD+ injections are suitable for you.
Long-Term Effects: While NAD+ injections are generally well-tolerated, more research is needed to fully understand their long-term effects and safety profile.

‍